Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: Pharmacokinetics and 24-week safety and efficacy

Pediatric Infectious Disease Journal

Volumn 28, Issue 3, 2009, Pages 215-219

  Chadwick, Ellen Gould ^a   Pinto, Jorge ^b   Yogev, Ram ^a   Alvero, Carmelita G ^c   Hughes, Michael D ^c   Palumbo, Paul ^d   Robbins, Brian ^e,k   Hazra, Rohan ^f   Serchuck, Leslie ^f   Heckman, Barbara E ^g   Purdue, Lynette ^h   Browning, Renee ^h   Luzuriaga, Katherine ⁱ   Rodman, John ^e   Capparelli, Edmund ^j  

^a Division of Infectious Disease   (United States)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^g FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

more..

Author keywords

Infants, HIV 1; Lopinavir ritonavir; Pharmacokinetics

Indexed keywords

CHOLESTEROL; DIDANOSINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE; TRIACYLGLYCEROL; VIRUS RNA; ZIDOVUDINE; LOPINAVIR; PROTEINASE INHIBITOR; PYRIMIDINONE DERIVATIVE; RITONAVIR;

AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INDICATION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; BLOOD; DRUG ADMINISTRATION; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY;

AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; MALE; PYRIMIDINONES; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 63449084340     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31818cc053     Document Type: Article

References (18)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). AIDS epidemic update: December 2007. Available at: http://dataunaids.org/pub/EPISlides/2007/2007-epiupdate-en.pdf Accessed May 21, 2008.
2. Newell ML, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2004;364:1236-1243.
3. Mphatswe W, Blanckenberg N, Tudor-Williams G, et al. High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. AIDS. 2007;21:1253-1261.
4. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233-2244.
5. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. New Engl J Med. 2007;356:135-147.
6. Chadwick EG, Capparelli EV, Yogev R, et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS. 2008;22:249-255.
7. Division of AIDS (DAIDS). Table for grading severity of pediatric (≤3 months of age) adverse experiences: April 1994. Available at: http://rcc.tech-res.com/ DAIDS%20RCC%20Forms/ToxicityTables-Pediatric- Under3MonthsAge-v02.pdf Accessed May 21, 2008.
8. Capparelli EV, Sullivan JL, Mofenson L, et al. Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants. Pediatr Infect Dis J. 2001;20:746-751.
9. Chadwick EG, Rodman JH, Britto P, et al. Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age. Pediatr Infect Dis J. 2005;24:793-800.
10. Kashuba ADM, Shapiro J, Burger DM. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther. 2006;3:4-14.
11. D'Argenio DZ, Schumitzky A. ADAPT II user's guide: pharmacokinetic/ pharmacodynamic systems analysis software. Los Angeles, CA; Biomedical Simulations Resource; 1997.
12. Yen-Lieberman B, Brambilla D, Jackson B, et al. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J Clin Microbiol. 1996;34:2695-2701.
13. Division of AIDS. Table for grading the severity of adult and pediatric adverse events. December, 2004. Available at: http://rcc.tech-res.com/ DAIDS%20RCC% 20Forms/ToxicityTables-DAIDS-AE-GradingTable-FinalDec2004.pdf Accessed May 21, 2008.
14. Newell ML, Patel D, Goetghebuer T, et al; European Collaborative Study. CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: Is it associated with age at initiation? J Infect Dis. 2006;193:954-962.
15. World Health Organization (WHO) 2006. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access by 2010. How WHO is working with countries to scale-up HIV prevention, treatment, care and support. Available at: http://www.who.int/hiv/ toronto2006/towardsuniversalaccess.pdf Accessed May 21, 2008.
16. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 2001;15:F1-F9.
17. HIV Pediatric Prognostic Markers Collaborative Study. Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data. Lancet. 2005;366: 1868-1874.
18. Saez-Llorens X, Violari A, Deetz CO, et al. Forty-eight week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003;22:216-223.